Concepedia

V. Sandor

VS

Statistics

Publications

13

Citations

3.3K

H-Index

12

Active since

1998

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of Toronto

Princess Margaret Cancer Centre

Stanford Cancer Institute

Novartis (Switzerland)

V. Sandor is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacology, and oncology.

Publications per year

1998–2019

13

Publications

13

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Haematologica · 2015 · 329 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

P21-dependent G1arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

V. Sandor, Adrian M. Senderowicz, Susan D. Mertins et al. · British Journal of Cancer · 2000 · 288 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Alessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian et al. · Haematologica · 2015 · 253 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.

V. Sandor, Virginia Stark-Vancs, Deborah A. Pearson et al. · Journal of Clinical Oncology · 1998 · 237 citations

Medicine, Oncology, Radiation Oncology +17

1–5 of 13